Advertisement Press Releases Archive - Page 2 of 231 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Pressreleases

Search

  • 11 Dec 2024
    Gerresheimer Successfully Completes Acquisition of Blitz LuxCo, the Holding Company of the Bormioli Pharma Group

    Gerresheimer Successfully Completes Acquisition of Blitz LuxCo, the Holding Company of the Bormioli Pharma Group

    By Nat Schaefer

    Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and cosmetics industries, has successfully completed the acquisition of Blitz LuxCo, the holding company of the Bormioli Pharma Group announced in May 2024. The closing was preceded by the fulfillment of customary closing conditions. Bormioli Pharma has a portfolio of pharmaceutical primary packaging made of glass and plastic as well as closure solutions, accessories and dosing systems that is complementary to Gerresheimer.

  • 03 Dec 2024
    Gerresheimer Builds New Production Capacities for Glass Syringes at Skopje Site

    Gerresheimer Builds New Production Capacities for Glass Syringes at Skopje Site

    By Nat Schaefer

    Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetics industries, is expanding its production capacity in Skopje, North Macedonia, with a new production hall for syringes. Since 2019, Gerresheimer has been producing drug delivery systems, diagnostic and medical products made of plastic on around 14,600m² at this site. The new factory hall adds around 7,600m² of production space for glass syringes.

  • 11 Nov 2024
  • 29 Oct 2024
  • 24 Sep 2024
    Gerresheimer Gx Elite Vials: Best Drug Protection and Production Efficiency

    Gerresheimer Gx Elite Vials: Best Drug Protection and Production Efficiency

    By Nat Schaefer

    Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industries, is presenting Gx Elite vials, designed to maximise patient safety and production efficiency through a quality by design approach. The main advantages of the product are its superior quality, which is reflected, for example, in its high breakage resistance and production efficiency. The advanced primary packaging solution is particularly suitable for sophisticated drugs such as biopharmaceuticals and innovative vaccines. Gx Elite vials can be delivered in bulk or pre-sterilised ready-to-fill in Gerresheimer’s innovative EZ-fill Smart packaging.

  • 16 Sep 2024
    Gerresheimer: EcoVadis Gold with Further Improved Score

    Gerresheimer: EcoVadis Gold with Further Improved Score

    By Nat Schaefer

    Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and cosmetics industries, has once again been awarded Gold by the sustainability rating provider EcoVadis. EcoVadis evaluates the management systems of companies in the categories of environment, labour and human rights, ethics, and sustainable procurement. More than 130,000 companies worldwide have their sustainability performance assessed by EcoVadis.

  • 02 Sep 2024
    Gerresheimer: Innovative Silicone Oil-Free Syringe Systems for Sensitive Ophthalmic Drugs

    Gerresheimer: Innovative Silicone Oil-Free Syringe Systems for Sensitive Ophthalmic Drugs

    By Nat Schaefer

    Gerresheimer, an innovative systems and solutions provider and global partner for the pharma and biotech industry, will be presenting its innovative silicone oil-free prefillable syringe systems for ophthalmic applications at CPHI Worldwide 2024. The syringe systems made of glass or plastic ensure maximum compatibility even for sensitive ophthalmic drugs and offer outstanding functionality with precise dosage.

  • 11 Jul 2024
    Gerresheimer Remains on Track in First Half of 2024

    Gerresheimer Remains on Track in First Half of 2024

    By Nat Schaefer

    Gerresheimer, an innovative systems and solutions provider and global partner for the pharmaceutical, biotechnology and cosmetic industries, remains on track in the first half (H1) of FY 2024. Revenues reached €968.5m (H1 2023: €957.4m), adjusted EBITDA €188.2m (H1 2023: €185.2m). Revenue growth was 1.7% and adjusted EBITDA growth was 2.9% in organic terms. The adjusted EBITDA margin was 19.4%. Destocking effects for customers in the Primary Packaging Glass division were offset by the good revenue performance with a significantly improved margin in the Plastics & Devices division.

  • 08 Jul 2024
  • 26 Jun 2024
‹1234›»